Asarina Pharma ApS: Financial statements 2018
CVR: 38495712
Source: annual report 2018, Danish Business Authority
01/01/2018 – 31/12/2018
Asarina Pharma ApS (CVR 38495712) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK -891,919,000 and a net result of DKK -31,279,340,000. Equity in the 2018 report amounted to DKK 12,062,389,000. The solvency ratio was 20.3%.
- Gross Profit
- DKK -891,919,000
- Profit/Loss
- DKK -31,279,340,000
- Equity
- DKK 12,062,389,000
- Total Assets
- DKK 59,471,888,000
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
Asarina Pharma ApS has published its interim report for the period March 16, 2017 – December 31, 2017.
As of May 28, 2018, Jakob Dynnes Hansen has joined the board of directors of Asarina Pharma ApS.
As of May 28, 2018, Peter Hviid Nordkild has joined the board of directors of Asarina Pharma ApS.
As of May 28, 2018, Miroslav Reljanovic has left the board of directors of Asarina Pharma ApS.
As of May 28, 2018, Claude Thierry Laugel has left the board of directors of Asarina Pharma ApS.
As of May 28, 2018, Erik Graham Fagg has left the board of directors of Asarina Pharma ApS.
As of May 28, 2018, Sten Gunnar Otto Skolling has left the board of directors of Asarina Pharma ApS.
As of May 28, 2018, Paul Karl Mikael de Potocki is registered as chairman of Asarina Pharma ApS.
As of May 28, 2018, Ola Gösta Flink has stepped down as chairman of Asarina Pharma ApS.
About Asarina Pharma ApS
Asarina Pharma ApS was a Danish company of the type Anpartsselskab based in Charlottenlund, founded in 2017. The company has been dissolved on 30 June 2026. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Asarina Danmark ApS. The company has 1 employee (2025). In 2024, the company reported a gross profit of DKK -365,453 and a net result of DKK -1,333,232 compared with DKK -42,903,193 the year before. Equity in the 2024 report amounted to DKK -107,343.